Literature DB >> 11956948

Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.

H-Q Wu1, A Rassoulpour, R Schwarcz.   

Abstract

Dopaminergic stimulation, caused by direct dopamine receptor agonists or by indirectly acting agents such as d-amphetamine or methylphenidate, causes a functionally significant decrease in the concentration of kynurenate (KYNA), an astrocyte-derived endogenous antagonist of both N-methyl-D-aspartate (NMDA) and alpha7 nicotinic acetylcholine receptors, in the rat brain. The present study was designed to examine if this effect can be duplicated by the systemic administration of dopamine's bioprecursor L-DOPA. Experiments were conducted in unanesthetized rats, and the extracellular levels of KYNA were determined in striatal microdialysate samples. L-DOPA caused a dose-dependent, transient reduction in striatal KYNA, reaching a nadir of -37.5% 1.5 h after the administration of 200 mg/kg of the drug. This effect was abolished in animals with a 6-hydroxydopamine-induced lesion of the nigrostriatal pathway, but was not influenced by a prior striatal quinolinate lesion. These data confirm the dopaminergic control of striatal KYNA formation and suggest that the interactions are mediated by astrocytic dopamine receptors. This modulation of striatal KYNA levels might provide a link between dopaminergic, glutamatergic and cholinergic neurotransmission in the normal and diseased striatum.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956948     DOI: 10.1007/s007020200020

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  6 in total

1.  Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease.

Authors:  Kuo-Hsuan Chang; Mei-Ling Cheng; Hsiang-Yu Tang; Cheng-Yu Huang; Yih-Ru Wu; Chiung-Mei Chen
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

2.  The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.

Authors:  Hannah F Iaccarino; Raymond F Suckow; Shan Xie; David J Bucci
Journal:  Schizophr Res       Date:  2013-09-30       Impact factor: 4.939

3.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 4.  Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.

Authors:  Dénes Zádori; Levente Szalárdy; József Toldi; Ferenc Fülöp; Péter Klivényi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-11-30       Impact factor: 3.575

5.  Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder.

Authors:  Nicholas W S Davies; Gilles Guillemin; Bruce J Brew
Journal:  Int J Tryptophan Res       Date:  2010-06-10

6.  Chronic Antipsychotic Treatment in the Rat - Effects on Brain Interleukin-8 and Kynurenic Acid.

Authors:  Markus K Larsson; Lilly Schwieler; Michel Goiny; Sophie Erhardt; Göran Engberg
Journal:  Int J Tryptophan Res       Date:  2015-09-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.